Can a No-Fridge migraine shot replace botox?

NCT ID NCT05598723

Recruiting now Disease control Sponsor: Naval Medical Center Camp Lejeune Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether incobotulinumtoxinA (Xeomin), a botulinum toxin that does not require refrigeration, works as well as onabotulinumtoxinA (Botox) for preventing chronic migraine. Adults with 15 or more headache days per month will receive injections of either drug at two time points. The study aims to find a more portable alternative to Botox for people who need migraine prevention but lack access to cold storage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: botulinum toxin type A (either onabotulinumtoxinA or incobotulinumtoxinA)
What this could lead to: If Xeomin works as well as Botox, it could offer a more portable treatment option for chronic migraine, especially for military personnel in remote settings.
What could go wrong: This is a relatively small trial, and Xeomin is not yet FDA-approved for migraine. It may prove less effective or have different side effects than Botox.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MIGRAINE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Naval Medical Center Camp Lejeune
RECRUITING

Jacksonville, North Carolina, 28547, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.